指南与共识类风湿关节炎

糖皮质激素、传统合成与靶向合成改善病情抗风湿药治疗类风湿关节炎的疗效:2016年EULAR推荐更新的系统文献综述

Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
指南 / 共识 · Ann Rheum Dis · 2017-03-29

该系统文献综述纳入2013至2016年间随机对照试验,评估糖皮质激素、传统合成改善病情抗风湿药(csDMARDs)及靶向合成改善病情抗风湿药(tsDMARDs,托法替布与巴瑞替尼)治疗类风湿关节炎的疗效。结论提示加用糖皮质激素可能获益但需权衡毒性,严密控制下甲氨蝶呤单药不劣于csDMARDs联合且耐受性更好,托法替布与巴瑞替尼有效。

要点

  • 加用糖皮质激素可能获益,但需与毒性风险相平衡。
  • 严密控制条件下甲氨蝶呤单药不劣于csDMARDs联合治疗且耐受性更好。
  • 托法替布与巴瑞替尼对类风湿关节炎患者有效,包括难治性患者。

核心结论

  • 加用糖皮质激素可能有益,但获益应与毒性风险权衡。
  • 严密控制下甲氨蝶呤单药不劣于csDMARDs联合治疗,且耐受性更好。
  • 托法替布与巴瑞替尼对类风湿关节炎患者有效,包括难治性疾病患者。

研究设计与样本

  • 系统文献综述,检索2013至2016年间随机临床试验,为2016年EULAR类风湿关节炎管理推荐更新提供依据。

主要发现

  • 糖皮质激素方面纳入4项研究,无不良预后因素患者加用糖皮质激素至甲氨蝶呤后获益,低剂量与高剂量相似。
  • csDMARDs方面纳入2项比较甲氨蝶呤单药与csDMARDs联合的新研究。
  • tREACH试验12个月时按达标治疗原则严密控制,各组疾病活动度、功能能力和影像学进展无差异。
  • CareRA试验中csDMARDs联合治疗不优于甲氨蝶呤单药,且单药耐受性更好。
  • 托法替布与巴瑞替尼在不同患者人群中较安慰剂(甲氨蝶呤)更有效。

关键数值与推荐

  • 糖皮质激素:4项研究;无不良预后因素患者甲氨蝶呤加用糖皮质激素获益,低剂量与高剂量相似。
  • csDMARDs:2项新研究;tREACH试验12个月时各组疾病活动度、功能能力与影像学进展无差异;CareRA试验联合治疗不优于甲氨蝶呤单药且单药耐受性更好。
  • tsDMARDs:托法替布与巴瑞替尼在不同患者人群中较安慰剂(甲氨蝶呤)更有效。

临床怎么用

  • 对无不良预后因素的类风湿关节炎患者,可考虑在甲氨蝶呤基础上加用糖皮质激素,但须权衡毒性风险。
  • 在严密控制(达标治疗)条件下,甲氨蝶呤单药可作为不劣于csDMARDs联合且耐受性更好的选择。
  • 托法替布与巴瑞替尼可用于类风湿关节炎患者,包括难治性疾病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To perform a systematic literature review (SLR) informing the 2016 update of the recommendations for the management of rheumatoid arthritis (RA). METHODS: An SLR for the period between 2013 and 2016 was undertaken to assess the efficacy of glucocorticoids (GCs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and targeted synthetic DMARDs (tsDMARDs) (tofacitinib and baricitinib) in randomised clinical trials. RESULTS: For GCs, four studies were included in the SLR. Patients without poor prognostic factors experienced benefit when GCs were added to methotrexate (MTX). Lower doses of GCs were similar to higher doses. For csDMARDs, two new studies comparing MTX monotherapy with combination csDMARD were included in the SLR. In the tREACH trial at the end of 12 months no difference between the groups in disease activity, functional ability and radiographic progression was seen, using principles of tight control (treat-to-target). In the CareRA trial, combination therapy with csDMARDs was not superior to MTX monotherapy and monotherapy was better tolerated.For tsDMARDs, tofacitinib and baricitinib were shown to be more effective than placebo (MTX) in different patient populations. CONCLUSIONS: Addition of GCs to csDMARD therapy may be beneficial but the benefits should be balanced against the risk of toxicity. Under tight control conditions MTX monotherapy is not less effective than combination csDMARDs, but better tolerated. Tofacitinib and baricitinib are efficacious in patients with RA, including those with refractory disease.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chatzidionysiou K, Emamikia S, Nam J, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28356243. doi:10.1136/annrheumdis-2016-210711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。